Xiaotian M Zhang

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist

N. Chalasani, T. Hardy, S. Pillai, 2018, Hepatology communications.

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

N. Chalasani, T. Hardy, S. Pillai, 2017, Diabetes, obesity & metabolism.

Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting

E. Seaquist, S. Weisnagel, R. Rabasa-Lhoret, 2018, Diabetes, obesity & metabolism.

Anti-Oxidative Stress Effect of Loading-Dose Rosuvastatin Prior to Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Prospective Randomized Controlled Clinical Trial

F. Cao, Qian Zhang, Yundai Chen, 2014, Clinical Drug Investigation.

Tirzepatide Once Weekly for the Treatment of Obesity.

L. Aronne, I. Lee, J. Ard, 2022, The New England journal of medicine.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

N. Sattar, W. Garvey, C. L. le Roux, 2023, The Lancet.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

I. Lee, J. Ard, J. Rosenstock, 2023, The Lancet.